贝达喹啉/氯法齐明组合可能增强临床相关非结核分枝杆菌治疗活性
该体外研究测定了贝达喹啉对30株临床相关非结核分枝杆菌(NTM)及结核分枝杆菌的MIC,并用棋盘法和时间杀菌曲线评估其与氯法齐明、克拉霉素的联合作用。结果显示贝达喹啉对NTM活性中等,与氯法齐明联合对脓肿分枝杆菌(MAB)和鸟分枝杆菌复合群(MAC)可能增加活性,但与克拉霉素联合对MAC可能降低活性。
要点
- 贝达喹啉对NTM的MIC范围为<0.007至1 mg/L,活性中等。
- 贝达喹啉/氯法齐明对MAB和MAC可能增加活性。
- 贝达喹啉/克拉霉素对MAC可能较单药活性降低。
核心结论
- 基于体外数据,贝达喹啉/氯法齐明组合可能为MAB和MAC治疗增加活性。
- 贝达喹啉/克拉霉素组合对MAC的治疗活性可能低于贝达喹啉单药。
研究设计与样本
- 体外研究,采用肉汤微量稀释法测定30株临床相关NTM及结核分枝杆菌的贝达喹啉MIC。
- 对22株MAB和MAC参考株及临床分离株进行棋盘法联合药敏试验。
- 对MAB CIP 104536和鸟分枝杆菌ATCC 700898进行时间杀菌曲线试验,并监测贝达喹啉耐药。
主要发现
- 贝达喹啉对受试NTM的MIC在<0.007至1 mg/L之间。
- 贝达喹啉与受试药物对MAB或MAC均未显示相互作用;MAB与氯法齐明的最低平均FICI为0.79,MAC与氯法齐明为0.97、与克拉霉素为0.82。
- 时间杀菌曲线中贝达喹啉呈抑菌效应;氯法齐明延长对MAB的抑菌活性,对鸟分枝杆菌产生轻微杀菌效应。
- 贝达喹啉/氯法齐明延缓鸟分枝杆菌对贝达喹啉耐药的出现,但促进MAB耐药。
- 相对Bliss独立模型,贝达喹啉/氯法齐明对MAB随时间显示协同作用,对鸟分枝杆菌无交互作用;贝达喹啉/克拉霉素对鸟分枝杆菌显示拮抗作用。
临床怎么用
- 对于MAB和MAC感染,贝达喹啉/氯法齐明组合可能作为增加活性的候选方案,但需临床研究验证。
- 避免对MAC感染使用贝达喹啉/克拉霉素组合,因其体外活性可能低于贝达喹啉单药。
局限性
- 结论基于体外数据,尚未在临床研究中验证。
- 耐药监测仅针对特定菌株,需进一步评估耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-tuberculous mycobacteria (NTM) infections are hard to treat. New antimicrobial drugs and smarter combination regimens are needed. OBJECTIVES: Our aim was to determine the in vitro activity of bedaquiline against NTM and assess its synergy with established antimycobacterials. METHODS: We determined MICs of bedaquiline for clinically relevant NTM species and Mycobacterium tuberculosis by broth microdilution for 30 isolates. Synergy testing was performed using the chequerboard method for 22 reference strains and clinical isolates of Mycobacterium abscessus (MAB) and Mycobacterium avium complex (MAC). Time-kill kinetics (TK) assays with resistance monitoring of bedaquiline alone and combined with clofazimine were performed for MAB CIP 104536 and M. avium ATCC 700898; bedaquiline/clarithromycin combinations were evaluated against M. avium ATCC 700898. Interactions were assessed for TK experiments based on Bliss independence. RESULTS: Bedaquiline had modest activity against tested NTM, with MICs between <0.007 and 1 mg/L. Bedaquiline showed no interaction with tested drugs against MAB or MAC. Lowest mean fractional inhibitory concentration index (FICI) values were 0.79 with clofazimine for MAB and 0.97 with clofazimine and 0.82 with clarithromycin for MAC. In TK assays, bedaquiline showed a bacteriostatic effect. Clofazimine extended the bacteriostatic activity of bedaquiline against MAB and yielded a slight bactericidal effect against M. avium. The bedaquiline/clofazimine combination slowed emergence of bedaquiline resistance for M. avium but promoted it for MAB. Relative to Bliss independence, bedaquiline/clofazimine showed synergistic interaction over time for MAB and no interaction for M. avium and bedaquiline/clarithromycin showed antagonistic interaction for M. avium. CONCLUSIONS: Following these in vitro data, a bedaquiline/clofazimine combination might add activity to MAB and MAC treatment. The bedaquiline/clarithromycin combination might have lower activity compared with bedaquiline alone for MAC treatment.
引用
- Ruth MM, Sangen JJN, Remmers K, et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019. PMID: 30649327. doi:10.1093/jac/dky526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。